Bio-Rad Laboratories (BIO) 10-Q2016 Q1 Quarterly report

Filed: 6 May 16, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: agent, BioPlex, Brazilian, concurrent, cytometer, cytometry, Discovery, eliminated, enhanced, EU, Euro, geographic, initially, investee, investor, lab, mediation, moratorium, negotiated, newly, notably, novice, partly, preliminary, Pub, seller, statement, today, Trial, unanimously, uncertainty, unconsolidated, understand, unlimited, usage, view, withholding

Removed: achieved, area, chromatography, closure, depreciation, disease, disproportionately, DNA, estimating, force, fourth, framework, headcount, hedged, inherent, innovative, larger, leadership, negligible, reach, reached, resolve, role, selected, sequencing, Spanish, standard, tangible, underperforming, voluntarily, workflow

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

BIO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

Certification of Periodic Report

I, Christine A. Tsingos, Chief Financial Officer of Bio-Rad Laboratories, Inc. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:


(1)	the Quarterly Report on Form 10-Q of the Company for the quarter ended March 31, 2016 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and


(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date:	May 6, 2016	/s/ Christine A. Tsingos
		Christine A. Tsingos
		Executive Vice President,
		Chief Financial Officer

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.